Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of nirogacestat in recurrent ovarian granulosa cell tumor
2022-001816-25Phase 2Completed
- Sponsor
- SpringWorks Therapeutics
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nirogacestat in ovarian granulosa cell tumor (OGCT), sponsored by SpringWorks Therapeutics. Primary endpoint: Objective response rate (ORR). Started Oct 2022; status: completed.
02
Drugs
nirogacestat
03
Conditions
ovarian granulosa cell tumor (OGCT)
Beyond the preview
Go deeper on 2022-001816-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001816-25.